Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata-MedSci.cn

Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata

King, B; Mesinkovska, NA; Senna, MM; Mostaghimi, A; Hamilton, C; Cassella, J

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023; 89 (3): AB85

科室
- - 订阅+
  - 更多科室
工具
服务